移动健康干预对非酒精性脂肪肝的疗效--随机对照试验的 Meta 分析。

IF 2.6 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Clinics and research in hepatology and gastroenterology Pub Date : 2024-07-29 DOI:10.1016/j.clinre.2024.102433
Rohit Kumar , Monika Rani , Ramsha , Vanesh Kumar , Sahil Kumar , Johar Abbas , Savanti , Monika Kumari , Aakash Kumar , Santosh , Muhammad Sohaib Asghar
{"title":"移动健康干预对非酒精性脂肪肝的疗效--随机对照试验的 Meta 分析。","authors":"Rohit Kumar ,&nbsp;Monika Rani ,&nbsp;Ramsha ,&nbsp;Vanesh Kumar ,&nbsp;Sahil Kumar ,&nbsp;Johar Abbas ,&nbsp;Savanti ,&nbsp;Monika Kumari ,&nbsp;Aakash Kumar ,&nbsp;Santosh ,&nbsp;Muhammad Sohaib Asghar","doi":"10.1016/j.clinre.2024.102433","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Lifestyle modification is the mainstay of management, however, most patients find it difficult to significantly modify their lifestyle. Mobile health is an innovative healthcare system that has an established role in treating chronic diseases like asthma, cancer and cardiovascular disease. Hence, we conducted an updated meta analysis to evaluate the efficacy of mobile health intervention (mHI) for NAFLD.</p></div><div><h3>Methods</h3><p>Literature search of five electronic databases was performed from the inception of the paper till 15th May, 2024. Studies were included if they met the inclusion criteria; Randomized controlled trials evaluating use of mHI along with standard care in comparison to standard care only for patients with NAFLD over 18 years. Primary outcomes of interest included changes in weight, body mass index (BMI), and liver markers from baseline to post intervention. Risk of bias was evaluated using the Cochrane bias assessment tool while the Mantel-Haenszel Random-effects model on Review manager was used to pool outcomes.</p></div><div><h3>Results</h3><p>Outcomes were pooled from 7 RCTs comprising a total of 621 participants. There was a significant decrease in weight (P &lt; 0.0001), aspartate aminotransferase (AST) (P = 0.002) and alkaline aminotransferase (ALT) (P = 0.0009) from baseline to follow-up in the intervention group as compared to the control group. However, the reduction in BMI was found to be non-significant (P = 0.64).</p></div><div><h3>Conclusion</h3><p>Our meta analysis reports that mHI plays an important role in significantly reducing weight and liver markers in patients with NAFLD. Considering that the improvement of these factors plays a key role in the management of the disease, mHI could be the key towards paving better outcomes for patients with NAFLD.</p></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"48 8","pages":"Article 102433"},"PeriodicalIF":2.6000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of mobile health intervention for non alcoholic fatty liver disease- A meta analysis of randomized controlled trials\",\"authors\":\"Rohit Kumar ,&nbsp;Monika Rani ,&nbsp;Ramsha ,&nbsp;Vanesh Kumar ,&nbsp;Sahil Kumar ,&nbsp;Johar Abbas ,&nbsp;Savanti ,&nbsp;Monika Kumari ,&nbsp;Aakash Kumar ,&nbsp;Santosh ,&nbsp;Muhammad Sohaib Asghar\",\"doi\":\"10.1016/j.clinre.2024.102433\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Lifestyle modification is the mainstay of management, however, most patients find it difficult to significantly modify their lifestyle. Mobile health is an innovative healthcare system that has an established role in treating chronic diseases like asthma, cancer and cardiovascular disease. Hence, we conducted an updated meta analysis to evaluate the efficacy of mobile health intervention (mHI) for NAFLD.</p></div><div><h3>Methods</h3><p>Literature search of five electronic databases was performed from the inception of the paper till 15th May, 2024. Studies were included if they met the inclusion criteria; Randomized controlled trials evaluating use of mHI along with standard care in comparison to standard care only for patients with NAFLD over 18 years. Primary outcomes of interest included changes in weight, body mass index (BMI), and liver markers from baseline to post intervention. Risk of bias was evaluated using the Cochrane bias assessment tool while the Mantel-Haenszel Random-effects model on Review manager was used to pool outcomes.</p></div><div><h3>Results</h3><p>Outcomes were pooled from 7 RCTs comprising a total of 621 participants. There was a significant decrease in weight (P &lt; 0.0001), aspartate aminotransferase (AST) (P = 0.002) and alkaline aminotransferase (ALT) (P = 0.0009) from baseline to follow-up in the intervention group as compared to the control group. However, the reduction in BMI was found to be non-significant (P = 0.64).</p></div><div><h3>Conclusion</h3><p>Our meta analysis reports that mHI plays an important role in significantly reducing weight and liver markers in patients with NAFLD. Considering that the improvement of these factors plays a key role in the management of the disease, mHI could be the key towards paving better outcomes for patients with NAFLD.</p></div>\",\"PeriodicalId\":10424,\"journal\":{\"name\":\"Clinics and research in hepatology and gastroenterology\",\"volume\":\"48 8\",\"pages\":\"Article 102433\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinics and research in hepatology and gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2210740124001542\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics and research in hepatology and gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2210740124001542","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介:非酒精性脂肪肝(NAFLD)是全球最常见的慢性肝病:非酒精性脂肪肝是全球最常见的慢性肝病。改变生活方式是治疗的主要方法,但大多数患者发现很难大幅改变生活方式。移动医疗是一种创新的医疗保健系统,在治疗哮喘、癌症和心血管疾病等慢性疾病方面发挥着既定的作用。因此,我们进行了一项最新的荟萃分析,以评估移动医疗干预(mHI)对非酒精性脂肪肝的疗效:方法:从本文开始至 2024 年 5 月 15 日,我们在五个电子数据库中进行了文献检索。符合纳入标准的研究均被纳入;针对 18 岁以上非酒精性脂肪肝患者,评估移动健康干预与标准护理的使用情况的随机对照试验。主要研究结果包括体重、体重指数 (BMI) 和肝脏指标从基线到干预后的变化。使用Cochrane偏倚评估工具对偏倚风险进行评估,同时使用Mantel-Haenszel随机效应模型对结果进行汇总:汇总了 7 项 RCT 的结果,共有 621 名参与者。与对照组相比,干预组的体重(P < 0.0001)、天门冬氨酸氨基转移酶(AST)(P = 0.002)和碱性氨基转移酶(ALT)(P = 0.0009)从基线到随访期间均有明显下降。然而,体重指数的降低并不显著(P= 0.64):我们的荟萃分析报告显示,mHI 在显著降低非酒精性脂肪肝患者的体重和肝脏指标方面发挥了重要作用。考虑到这些因素的改善在疾病管理中起着关键作用,mHI 可能是为非酒精性脂肪肝患者带来更好治疗效果的关键。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Effectiveness of mobile health intervention for non alcoholic fatty liver disease- A meta analysis of randomized controlled trials

Introduction

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Lifestyle modification is the mainstay of management, however, most patients find it difficult to significantly modify their lifestyle. Mobile health is an innovative healthcare system that has an established role in treating chronic diseases like asthma, cancer and cardiovascular disease. Hence, we conducted an updated meta analysis to evaluate the efficacy of mobile health intervention (mHI) for NAFLD.

Methods

Literature search of five electronic databases was performed from the inception of the paper till 15th May, 2024. Studies were included if they met the inclusion criteria; Randomized controlled trials evaluating use of mHI along with standard care in comparison to standard care only for patients with NAFLD over 18 years. Primary outcomes of interest included changes in weight, body mass index (BMI), and liver markers from baseline to post intervention. Risk of bias was evaluated using the Cochrane bias assessment tool while the Mantel-Haenszel Random-effects model on Review manager was used to pool outcomes.

Results

Outcomes were pooled from 7 RCTs comprising a total of 621 participants. There was a significant decrease in weight (P < 0.0001), aspartate aminotransferase (AST) (P = 0.002) and alkaline aminotransferase (ALT) (P = 0.0009) from baseline to follow-up in the intervention group as compared to the control group. However, the reduction in BMI was found to be non-significant (P = 0.64).

Conclusion

Our meta analysis reports that mHI plays an important role in significantly reducing weight and liver markers in patients with NAFLD. Considering that the improvement of these factors plays a key role in the management of the disease, mHI could be the key towards paving better outcomes for patients with NAFLD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
3.70%
发文量
198
审稿时长
42 days
期刊介绍: Clinics and Research in Hepatology and Gastroenterology publishes high-quality original research papers in the field of hepatology and gastroenterology. The editors put the accent on rapid communication of new research and clinical developments and so called "hot topic" issues. Following a clear Editorial line, besides original articles and case reports, each issue features editorials, commentaries and reviews. The journal encourages research and discussion between all those involved in the specialty on an international level. All articles are peer reviewed by international experts, the articles in press are online and indexed in the international databases (Current Contents, Pubmed, Scopus, Science Direct). Clinics and Research in Hepatology and Gastroenterology is a subscription journal (with optional open access), which allows you to publish your research without any cost to you (unless you proactively chose the open access option). Your article will be available to all researchers around the globe whose institution has a subscription to the journal.
期刊最新文献
Primary hepatic large B-cell lymphoma Safety and efficacy of the enhanced recovery after surgery protocol in hepatectomy for liver cancer Prolonged survival in women with hepatocellular carcinoma: A French observational study A Review Investigating delays in Crohn's disease diagnosis. Intra- and inter-patient diversity in hepatocellular carcinoma based on phosphorylation profiles—A pilot study in a single institution
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1